KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib
John C. Smith Laura Brooks; Paulo M Hoff; Gael McWalter; Simon Dearden; Shethah R Morgan; David Wilson; Jane D Robertson; Juliane M Jürgensmeier
European Journal of Cancer Oxford v. 49, n. 10, p. 2424-2432, 2013Oxford 2013
Localização: FM - Fac. Medicina (BCSEP 247 2013 )(Acessar)